MolMed: the Shareholders’ Meeting approves 2017 Financial Statements

PRESS RELEASE

MolMed: the Shareholders' Meeting approves 2017 Financial Statements

Favourable vote expressed on first section of the Remuneration Report pursuant to Article 123 of CFA

Milan (Italy), April 12nd 2018 - The Shareholders Meeting of MolMed S.p.A. (MLM.MI), medical biotechnology company focusing on research, development, manufacturing, and clinical validation of Cell & Gene therapies to treat cancer and rare diseases, met today under the chairmanship of Professor Claudio Bordignon, and resolved upon the items of the agenda as follows:

Approval of the Statutory Financial Statements for year 2017. Resolutions related and consequent thereto

The Financial Statement for period ended December 31st, 2017 with Operating Revenue equal to Euro 23,987 thousand (+5.1% compared to 2016), Revenue from Sales equal to 23,000 thousand (+18% compared to 2016) and Operating Costs equal to Euro 32,135 thousand (reduced by 11.7% compared to 2016), recorded an Operating Result negative for Euro 8,148 thousand (improved by 40% compared to 2016) and a Net Result negative for Euro 8,497 thousand (improved by 38.8% compared to the previous year). The Net Financial Position at December 31st 2017 is positive and equal to Euro 18,111 thousand (Euro 19,702 thousand at December 31st 2016) and consists of cash and current financial assets, in absence of financial indebtedness.

The Shareholders' Meeting, having duly noted the Statutory Auditors' and Independent Auditors' Reports, approved the Statutory Financial Statements for the fiscal year ended December 31st, 2017, as submitted, resolving to carry forward the overall loss of Euro 8,497 thousand.

Report on remuneration - Section I: resolution pursuant to art. 123-ter of CFA (Legislative Decree No. 58/1998)

The Shareholders' Meeting expressed a favourable opinion on the Section I of the Report on the remuneration policy pursuant to Article 123 of CFA. Section I of the above-mentioned Report details principles and purposes of the Company remuneration Policy for Board directors, general manager and strategic directors for FY 2018, as well as the related procedures implemented in order to adopt and implement the policy.

The report is also available on the company's websitehttp://www.molmed.com ***

Filing of documentation

In accordance with the provisions of art. 125-quater, paragraph 2, of the TUF and art. 77, paragraph 3, of the Issuers' Regulations, a summary report containing the number of voting shares represented at the meeting

FROM GENES TO THERAPY 1

and the actions for which the vote was cast, the percentage of capital that these shares represent, as well as the number of votes for and against the resolutions and the number of abstentions, will be made available to the public within five days from the date of the Shareholders' meeting on the Company's website.

***

The minutes of the Shareholders' Meeting will be made available to the public according to the terms provided by the laws and regulations in force.

***

The official manager responsible for preparing the Company's financial reports, Andrea Quaglino, herewith attests, pursuant to Article 154-bis, paragraph 2 of the Italian Consolidated Finance Act (Legislative Decree 58/1998, as amended), that the accounting disclosure contained in this press release matches documentary evidence, corporate books, and accounting records.

This press release is available on the company websitehttp://www.molmed.com

About MolMed

MolMed S.p.A. is a biotechnology company focused on research, development, manufacturing and clinical validation of innovative anticancer therapies. MolMed's product portfolio includes proprietary anti-tumor therapies in clinical and preclinical development: Zalmoxis® (TK) is a cell therapy based on donor T cells genetically engineered to enable bone marrow transplants from partially compatible donors for patients with high-risk hematological malignancies, eliminating post-transplant immunosuppression prophylaxis and inducing a rapid immune reconstitution. Zalmoxis® received Orphan Drug Designation and is currently in Phase III in a high-risk population of acute leukemia patients, but has already obtained a Conditional Marketing Authorization by the European Commission in the second half of 2016 as well as reimbursement conditions in Italy at the end of 2017 and in Germany at the beginning of 2018. Still focusing on this cell & gene technology, the company is developing a therapy based on Chimeric Antigen Receptor (CAR), specifically the CAR-T CD44v6, an immune gene therapy project, currently in advanced preclinical development, potentially effective for hematological malignancies and several solid epithelial tumors. MolMed is also the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies for its proprietary products (Zalmoxis®) as well as for third parties and/or in partnership (Strimvelis, a GSK gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. In the framework of innovative anticancer therapies, MolMed's pipeline also includes NGR-hTNF, a therapeutic agent for solid tumors investigated in a broad clinical program, involving more than 1,000 treated patients. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso.

FROM GENES TO THERAPY 2

For further information:

Ilaria Candotti

Investor Relations & Communication Manager MolMed S.p.A.

phone: [phone] fax: [phone] e-mail:[e-mail]

Marcella Ruggiero

Press agent

SEC Relazioni Pubbliche e Istituzionali s.r.l.

phone: [phone] mobile [phone] e-mail:[e-mail]

FROM GENES TO THERAPY

3